Insys Therapeutics (INSY) Misses Q2 EPS by 17c

Insys Therapeutics (NASDAQ: INSY) reported Q2 Adj. EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $38 million versus the consensus estimate of $25.91 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight